Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?

Kenneth Blum1-6,*, Marlene Oscar-Berman7, Seth H Blum8, Margaret A Madigan6, Roger L Waite6, Thomas McLaughlin9 and Debmalya Barh9

1Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA
2Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT, USA
3Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach, CA, USA
4Dominion Diagnostics, LLC, North Kingstown, RI, USA
5Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
6IGENE, LLC, Austin, Texas, USA
7Departments of Psychiatry, Neurology, and Anatomy & Neurobiology, Boston University School of Medicine, and Boston VA Healthcare System, Boston, MA, 02118, USA
8Department of Nutrigenomics, RDSolutions, LLC, La Jolla, CA, USA
9Center for Psychiatric Medicine, North Andover, Massachusetts, USA

An overwhelming segment of the world’s population possesses certain genetic variations that increase risk for genetic predispositions to substance seeking and even behavioral addictions (e.g. gambling, internet gaming, multiple sex partners etc.) that preclude them from reaching their optimum health potential, contribute to impaired health, and/or can cause involuntary indulgence in detrimental and self-destructive behaviors. This is especially true when this genetic reward deficiency (RDS) [1] problem leads to not only compulsions and excessive cravings but also impaired decision making. This brain hard wiring will ultimately lead to unwanted narcotic addictions; anti-social behavior; crime and unnecessary medical procedures that burden society [2].

It is our notion that the real genesis of all behavior, whether so-called normal or abnormal behavior, derives from an individual’s genetic makeup at birth involving gene variations that make up about 3% of the human genome. While people are not doomed because of carrying these so called variations (called alleles) this risk predisposition, due to multiple gene combinations and polymorphisms (gene variations), is expressed differently based on numerous environmental (epigenetic) elements. So carrying these known gene variants especially in those genes known to control what is called the “Brain Reward Cascade (BRC) influencing how the brain programs feelings of well-being, mediate the actual expression of these important genes [3].

It is well-established that psychiatric disorders are complex multifactorial illnesses involving chronic alterations in the brain reward circuitry. While it is agreed that genetic factors are important in the etiology of disorders such as RDS, relatively high rates of discordance among identical twins suggest the importance of other mechanisms. Certainly, environmental factors such as stress or prior drug exposure play a role in the onset of these illnesses. There is evidence that sustained abnormalities are maintained by epigenetic modifications in specific brain regions. Addictive behavior can be modeled in animals by inducing disease-like states through environmental manipulations (e.g., chronic stress, drug administration) [3].

As David Smith the founder of the Haight-Ashbury Clinic stated “Love Needs Care” and that is what positive caring has in common with powerful epigenetic effects. We firmly embrace this “love and care” concept as part of any treatment goal with the knowledge that through epigenetic effects either methylation and or deacetylation gene expression will lead to positive dopamine release at the reward centers of the brain [4]. Understanding the importance of epigenetics and its effects on chromatin structure will lead to new therapeutic targets to combat for example drug seeking behavior.

In fact, we promote the concept that the core of predisposition to these behaviors is a set of genes (called candidate genes), which mediate a feeling of well-being via chemical messenger (i.e. neurotransmitters) interaction at the “reward site” of the brain (N. Accumbens), leading to normal dopamine release and influencing dopamine receptor density (the actual number of dopamine receptors). A low number of Dopamine receptors suggest a hypodopaminergic function as manifested in all addictive disorders. When there are a low number of dopamine receptors, the person will be more prone to seek any substance or behavior that stimulates the dopaminergic system (a sort of “dopamine fix”). In fact, Nora Volkow the current director of the National Institutes of Drug Abuse (NIDA) stated that “all roads lead to dopamine” further described by Blum et al. [5].

To understand generalized craving behavior, due to hypodopaminergic function (a deficiency of reward responsiveness [blunted], individuals self-medicate through biochemical (illicit or non-illicit) attempts to alleviate or compensate for the low dopaminergic brain activity via drug-receptor activation (alcohol, heroin, cocaine, glucose, etc.) [6]. This will substitute for the lack of reward and yield a temporary compensatory sense of well-being. It is this low Dopamine genetic variant that sets these so called “Legacy Case” workers (see below) up for a predisposition for addiction. A very high percentage of these workers are involved in the “injury-treatment-medication-injury” revolving door cycle and may even carry genetic variants (serotonergic and dopaminergic) that result in a higher incident of accidents (e.g. driver accident tendentiousness) for these prone individuals [7].

In order to help explain this so called pseudo self-healing process, we are cognizant of known dysfunctional diagnosis known as “Legacy Cases.” These cases are a major problem within the Workers
Compensation insurance carriers systems. They are very similar to another dysfunctional diagnosis such as Fibromyalgia [8]. Legacy cases are patients with chronic pain that have a monthly narcotic cost of well-over $5,000 per month and have very low functionality in terms of daily living. These claims have been through the gambit of treatments (pharmaceutical, surgical, injections and rehabilitation) with little to no positive outcomes. One reason why these patients do not respond to traditional pain treatments is that they fall into a medical category of “Hypodopaminergic” or Reward Deficiency Syndrome (RDS) [9]. A major problem is that the neuro-circuits of their brains are incapable of having so called normal function of dopamine (called Homeostasis) so they become largely iatrogenic (clinically induced by legally prescribed opioids) addicts [10]. These patients just as the Fibromyalgia patients (which also seem not to respond to traditional therapies) require Dopamine Agonist Modalities (DAM). A number of clinical studies utilizing DAM have shown significant reversal of patients’ craving behavior, reduction of AMA (Against Medical Advice) rates; relapse prevention as well enhancement of quality of life during recovery including happiness (joy) [11].

One of the major underlying problems relating to these Legacy Cases is the inappropriate misdiagnosis and non-productive treatments these patients experience because of utilization of paper-pencil tests rather than sound candidate genetic testing [12]. We strongly believe that especially in low functioning “Legacy Cases” these patients may display high risk due to multiple gene variations across the brain including areas like the Pre-Frontal Cortex Cingulate Gyrus (a site of relapse due to decision making activity) as well the N. Accumbens (a site of craving behavior). Simply put many of the “Legacy Case” patients’ carry multiple gene variations (neurotransmitters and synthesis producing and metabolic genes) that lead to low Dopamine function (possibly reduced dopamine being released from nerve cells into the synapse (space between two nerve cells ) as well as synaptic high breakdown (catabolism) [13]. Correctly, reversing this condition and participating in appropriate treatments will balance their reward brain chemistry by increasing endogenously higher dopamine levels as well as dopamine’s overall reward function. The coupling of genetic testing to determine a person’s genetic risk for addiction and DAM in conjunction with other dopamine promoting effects (i.e. exercise, yoga, electrotherapy, cryotherapy, 12 steps, etc.) will result in pain reduction [14].

Our goal in terms of assisting insurance carriers is to reduce iatrogenic induced opioid addiction by reducing subsequent dependence on these powerful opiates such as even Suboxone thereby promoting “Legacy Case” closure [15]. Closure of these difficult cases will not only benefit the patient’s relief of addiction (craving) but will also reduce insurance carriers to return financial reserves held in abeyance back to the carrier’s general fund. Moreover, utilization of the Genetic Addiction Risk Score (GARS Rx™) ™ licensed to Dominion Diagnostics, LLC. Dr. Blum is also an officer and stock holder of Dominion Diagnostics, LLC. Dr. Blum is a paid consultant by IGENE LLC and is Chief Scientific Advisor of Dominion Diagnostics, LLC. Syntaptmine, Inc., the Nutrigenetic patent was licensed to RDSolutions for treatment of workers Compensation “Legacy Cases”. Roger L. Waite, Seth H Blum, Kenneth Blum are employed by RDSolutions. Margaret A. Madigan is a paid consultant by IGENE LLC.

Conclusion
To reiterate utilizing a new paradigm shift in both genetic testing and enhancing functional connectivity of the brain with DAM should improve the health and well-being of the “Legacy Claim” patients because the major underlying root causes of opiate dependency will be reduced. It will additionally curb abuse within the Workers’ Compensation Program and provide a significant monthly cost savings to the carrier and employer. In fact utilizing our approach in a hypodopaminergic genetically tested patient with GARS, having a workers Comp payment for medications over $50,000 per month has been successfully treated with DAM as well as other natural modalities, being opioid free for over two years [17]. Our main mission is to “redeeming joy”™ while inducing higher functionality leading to returning to the workforce. Following additional required research and further confirmation cautious interpretation is encouraged.

Acknowledgements
The writing of this paper was supported in part by funds from the National Institutes of Health, NIAAA (ROI-AA07112 and K05- AA00219) and the Medical Research Service of the US Department of Veterans Affairs (MOB). Kenneth Blum is the recipient of a grant to PATH FOUNDATION NY, by Life Extension Foundation, Ft/ Lauderdale, Florida.

Conflict of Interest
Kenneth Blum, PhD is the holder of a number of US and Foreign patents issued and pending related to Nutrigenomics and Nutraceuticals. Through IGENE LLC., Dr. Blum exclusively licensed the Genetic Addiction Risk Score (GARS Rx™) ™ to Dominion Diagnostics, LLC. Dr. Blum is also an officer and stock holder of IGENE, LLC and is a paid consultant of Dominion Diagnostics, LLC, IGENE, Malibu Recovery Center. Dr. Blum is a member of the scientific advisory board of Dominion Diagnostics, LLC and is Chief Scientific Advisor of Dominion Diagnostics, LLC. Syntaptmine, Inc., the Nutrigenetic patent was licensed to RDSolutions for treatment of workers Compensation “Legacy Cases”. Roger L. Waite, Seth H Blum, Kenneth Blum are employed by RDSolutions. Margaret A. Madigan is a paid consultant by IGENE LLC.

References
1. Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, et al. (2012) Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. J Genet Syndr Gene Ther 3: pii: 1000e115.
2. Cochran BN, Flentjé A, Heck NC, Van Den Bos J, Perlman D, et al. (2014) Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend 135: 252-258.
3. Peña CJ, Bagot RC, Labonté B, Nestler EJ (2014) Epigenetic Signaling in Psychiatric Disorders. J Mol Biol.
4. Maze I, Nestler EJ (2011) The epigenetic landscape of addiction. Ann N Y Acad Sci 1216: 99-113.
5. Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, et al. (2012) The addictive brain: all roads lead to dopamine. J Psychoactive Drugs 44: 134-143.
6. Slicc E, Yokum S (2013) Brain Reward Region Responsivity of Adolescents With and Without Parental Substance Use Disorders. Psychol Addict Behav.
7. Wang XM, Yang L, Zhang HY, Liu Y, Tang Zh, et al. (2012) [Association of 5-HTTLPR, DRD4 gene polymorphisms with the accident tendentiousness of drivers]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 30: 497-500.
8. Blum K, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, et al. (2014) A Multi-Step Approach to Treating Fibromyalgia by Boosting Dopaminergic
Activity in the Meso-Limbic System of the Brain. J Genet Syndr Gene Ther 5: 213.

9. Rovai L, Maremmani AG, Pacini M, Pani PP, Rugani F, et al. (2013) Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv Psichiatr 48: 1-9.

10. Blum K, Oscar-Berman M, Dinubile N, Giordano J, Braverman ER, et al. (2013) Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence. J Addict Res Ther 4: 1000163.

11. Blum K, Oscar-Berman M, Stulier E, Miller D, Giordano J, et al. (2012) Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. J Addict Res Ther 3: 139.

12. Alterman AI, Bovasso GB, Cacciola JS, McDermott PA (2001) A comparison of the predictive validity of four sets of baseline ASI summary indices. Psychol Addict Behav 15: 159-162.

13. Gardner EL (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30: 22-60.

14. Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, et al. (2009) Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses 72: 14-22.

15. Makhinson M, Gomez-Makhinson J (2014) A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. Am J Addict.

16. Blum K, Giordano J, Morse S, Anderson A, Carbajal J, et al. (2011) Hypothesizing Synergy between Acupuncture/Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse. IOAB Letters 1: 8-20.

17. Blum K, Oscar-Berman M, Femino J, Waite RL, Benya L, et al. (2013) Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. J Addict Res Ther 4.